Details

Autor(en) / Beteiligte

• Johnston, Sara C
• Ricks, Keersten M
• Lakhal-Naouar, Ines
• Jay, Alexandra
• Subra, Caroline
• Raymond, Jo Lynne
• King, Hannah A D
• Rossi, Franco
• Clements, Tamara L
• Fetterer, David
• Tostenson, Samantha
• Cincotta, Camila Macedo
• Hack, Holly R
• Kuklis, Caitlin
• Soman, Sandrine
• King, Jocelyn
• Peachman, Kristina K
• Kim, Dohoon
• Chen, Wei-Hung
• Sankhala, Rajeshwer S
• Martinez, Elizabeth J
• Hajduczki, Agnes
• Chang, William C
• Choe, Misook
• Thomas, Paul V
• Peterson, Caroline E
• Anderson, Alexander
• Swafford, Isabella
• Currier, Jeffrey R
• Paquin-Proulx, Dominic
• Jagodzinski, Linda L
• Matyas, Gary R
• Rao, Mangala
• Gromowski, Gregory D
• Peel, Sheila A
• White, Lauren
• Smith, Jeffrey M
• Hooper, Jay W
• Michael, Nelson L
• Modjarrad, Kayvon
• Joyce, M Gordon
• Nalca, Aysegul
• Bolton, Diane L
• Pitt, Margaret L M

Titel

A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model

Ist Teil von

• Vaccines (Basel), 2022-05, Vol.10 (5), p.717

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• The COVID-19 pandemic has had a staggering impact on social, economic, and public health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the etiologic agent of COVID-19) has been rapid. However, novel strategies are still necessary to slow the pandemic, and this includes new approaches to vaccine development and/or delivery that will improve vaccination compliance and demonstrate efficacy against emerging variants. Here, we report on the immunogenicity and efficacy of a SARS-CoV-2 vaccine comprising stabilized, pre-fusion spike protein trimers displayed on a ferritin nanoparticle (SpFN) adjuvanted with either conventional aluminum hydroxide or the Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque COVID-19 model. Vaccination resulted in robust cell-mediated and humoral responses and a significant reduction in lung lesions following SARS-CoV-2 infection. The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.